Osimertinib for EGFR‐Mutant Lung Cancer with Brain Metastases: Results from a Single‐Center Retrospective Study

INTRODUCTION. Osimertinib is a third‐generation tyrosine kinase inhibitor, initially approved for epidermal growth factor receptor (EGFR) mutant non‐small cell lung cancer (NSCLC) with T790M acquired resistance, and now approved in the first‐line setting. However, data supporting the use of osimerti...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Xie, Lijia, Nagpal, Seema, Wakelee, Heather A., Li, Gordon, Soltys, Scott G., Neal, Joel W.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2018
Assuntos:
Lung Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6656518/
https://ncbi.nlm.nih.gov/pubmed/30126856
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0264
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados